CTAGE3 Inhibitors
CTAGE3 inhibitors represent a class of chemical compounds that specifically target and inhibit the activity of the CTAGE3 protein, a member of the Cutaneous T-cell Lymphoma-associated Antigen (CTAGE) family. The CTAGE proteins are involved in various cellular processes, particularly in vesicle-mediated transport and the secretory pathway. CTAGE3, also known as Cutaneous T-cell Lymphoma-associated Antigen 3, plays a role in the regulation of protein trafficking between the endoplasmic reticulum (ER) and the Golgi apparatus. By influencing this transport, CTAGE3 is implicated in the maintenance of cellular homeostasis and the proper functioning of secretory pathways that are essential for the cellular export of proteins and lipids.
Inhibitors targeting CTAGE3 are typically small molecules designed to bind to the CTAGE3 protein, thus altering its function or preventing its interaction with other proteins involved in vesicular trafficking. These inhibitors are valuable tools for studying the mechanistic role of CTAGE3 in cellular processes, providing insights into how disruptions in protein transport can affect cell function. The chemical structure of CTAGE3 inhibitors can vary widely, but they generally share specific features that enable them to interact with the active sites or allosteric sites of the CTAGE3 protein. By selectively modulating the activity of CTAGE3, these inhibitors allow researchers to explore the protein's broader role in cellular physiology and its potential interactions with other molecular pathways within the cell. The development and refinement of CTAGE3 inhibitors are ongoing, with a focus on improving their specificity and efficacy in modulating CTAGE3-related pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor specifically designed to bind to the BCR-ABL protein in chronic myeloid leukemia. By inhibiting this protein, imatinib prevents the proliferation of cancer cells and induces their apoptosis. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib targets and inhibits the tyrosine kinase activity of the Epidermal Growth Factor Receptor (EGFR). Overactivity of EGFR is linked with cell proliferation in certain cancers. By inhibiting EGFR, gefitinib prevents cancer cell growth and division. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Doxorubicin intercalates into DNA, disrupting its function. It also inhibits topoisomerase II, an enzyme involved in DNA replication and repair. The disruption of these processes leads to DNA damage and, subsequently, cell death, particularly in rapidly dividing cells like cancer cells. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules in cells, preventing their normal breakdown during cell division. By inhibiting this process, paclitaxel effectively halts cell division, thus inhibiting cancer cell proliferation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin forms intrastrand and interstrand DNA cross-links, distorting the DNA structure. This DNA damage triggers apoptosis or cell death. Given its non-specific nature, it affects rapidly dividing cells, including cancer cells. | ||||||
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $76.00 $143.00 $469.00 $775.00 | 18 | |
Cyclophosphamide is a prodrug that, once metabolized, releases its active form which alkylates DNA. This alkylation process leads to DNA crosslinking, disrupting DNA replication and RNA transcription, thereby leading to cell death. It is non-specific and affects rapidly dividing cells. | ||||||
Temozolomide | 85622-93-1 | sc-203292 sc-203292A | 25 mg 100 mg | $89.00 $250.00 | 32 | |
Temozolomide is an alkylating agent that methylates DNA at the O6 position of guanine. This methylation can mispair with thymine during DNA replication, leading to DNA damage. If this damage isn't repaired properly, it can lead to cell death, specifically in cancer cells with defective DNA repair mechanisms. | ||||||
Melphalan | 148-82-3 | sc-204799 sc-204799A | 100 mg 250 mg | $136.00 $237.00 | 5 | |
Melphalan is another alkylating agent that introduces cross-links in DNA. This action interferes with DNA replication and RNA transcription. As a result, the cell's normal processes are disrupted, leading to apoptosis, especially in cells that are rapidly dividing, like cancer cells. | ||||||
Busulfan | 55-98-1 | sc-204658 | 10 g | $48.00 | 3 | |
Busulfan is an alkylating agent that cross-links DNA, leading to disruption in DNA replication and function. This results in cell cycle arrest and induces cell death. Busulfan mainly targets myeloid cells and is studied in the research of chronic myelogenous leukemia and in preparation for bone marrow transplantation. | ||||||